Spark Therapeutics Further Expands Gene Therapy Expertise with Appointment of Federico Mingozzi, Ph.D., as Chief …GlobeNewswire (press release)PHILADELPHIA, Sept. 25, 2017 (GLOBE NEWSWIRE) — Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene … Continue reading
PharmaTimes |
EU green light for Roche’s Tecentriq
PharmaTimes Roche has received European Commission approval for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab) to treat specific lung and bladder cancers. The green light means that it can be used as monotherapy for people in the EU with … |
Healio |
CAR T-cell therapy approval huge step for oncology, but only ‘beginning of story’
Healio Tisagenlecleucel — the first CAR T-cell therapy to demonstrate early, deep and durable remission in patients with relapsed/refractory ALL — likely will become the new standard of care for this population, according to Stephan A. Grupp, MD, PhD, Yetta … |
|
eTheRNA immunotherapies Awarded €1 Million Grant From Flanders Innovation & Entrepreneurship to Further …
PR Newswire (press release) eTheRNA immunotherapies, a clinical-stage company developing mRNA-based cancer immunotherapies from its unique TriMix platform, announces it has been awarded a €1 million industrial R&D Projects Grant by Flanders Innovation & Entrepreneurship … |
|
T-Cell Immunotherapy for Cancer Detailed Pipeline Analysis and In Depth Study with Companies Profiles
Medgadget (blog) According to RNCOS’ new research report “T-Cell Immunotherapy for Cancer – Pipeline Analysis”, T-cell immunotherapy is one of the most widely researched fields in the recent years. The high potential of T-cell based therapies to cure various types of … |
Nature.com |
Stem cells — masters of their fates
Nature.com Human glioblastomas (GBMs) are thought to harbour a subpopulation of glioblastoma stem cells (GSCs) that govern tumour initiation, maintenance and recurrence after therapy. Although homogeneous GSC populations can produce progenitors with diverse … |